## **SCANFIL**

07/17/2025 8:35 EEST


This is a translated version of the "Yritysostot kiristivät arvostuksen nopeasti" report, published on 07/17/2025



Antti Viljakainen +358 44 591 2216 antti.viljakainen@inderes.fi

**INDERES CORPORATE CUSTOMER** 

# **COMPANY REPORT**



## **Acquisitions quickly tightened the valuation**

We found the overall picture of Scanfil's Q2 report released yesterday to be fairly neutral. We added the ADCO and MB acquisitions, announced by the company in the summer, to our forecasts. Promising deals and putting the balance sheet to work raised our EPS estimates for the coming years by just over 10%. We nevertheless reiterate our Reduce recommendation for Scanfil, as the MB acquisition, in particular, boosted the share price this week and already pushed the valuation to fully priced (2026e: adj. EV/EBIT 11x). However, reflecting positive estimate revisions, we raise our target price to EUR 10.50 (was EUR 9.00).

#### There was no fuel for earnings growth yet in Q2

In Q2, Scanfil's revenue increased by 3% to 202 MEUR. Organically, we suspect revenue declined by some 1%, as the SRX acquisition supported revenue by some 4%, or 8.8 MEUR. In Q2, the adjusted EBITA decreased marginally to 14.2 MEUR. Profitability (adj. EBITA-%) was at Scanfil's baseline level of recent years, 7.0%. The improved earnings development from Q1 was slightly weaker than our somewhat overly optimistic expectations, but there was no major drama in the Q2 figures. The company managed to sell 42 MEUR of new projects in Q1, which was about 3% higher than in the comparison period. We commented on Scanfil's Q2 figures yesterday in more detail here.

#### **Acquisitions raised our estimates**

Scanfil reiterated its guidance of 2025 of 780-920 MEUR revenue and 55-68 MEUR adjusted EBIT. The guidance was in line with our expectations. Despite macroeconomic uncertainties, the company commented positively on the H2 outlook (as did Kitron and Note in their reports earlier in July). This was at least partly due to the improved outlook of project-driven customers. The guidance does not yet include the ADCO and MB acquisitions announced in the summer, but due to the development in H1, the positive H2 outlook despite the uncertainties, and the acquisitions only materializing in H2, we expect the company to maintain its guidance range throughout the year.

We added the ADCO and MB acquisitions to Scanfil's forecasts starting from Q3 and Q4, but organically, we made no significant changes to the company's growth and profitability forecasts after a fairly neutral Q2 report. The promising acquisitions and putting the strong balance sheet to work increased our adjusted EPS estimates for Scanfil in the coming years by over 10%. We expect that Scanfil's adjusted EPS will grow at a rate of some 15% by 2028, driven by acquisitions and organic growth enabled by a gradually recovering economic situation. The main risks for our forecasts are related to external demand factors such as the global economy. Internally, we believe the company is in fairly good shape, although we suspect the integration of two nearly simultaneous acquisitions will slightly increase the risk level associated with the company's operations in the coming quarters.

#### Valuation has tightened clearly since the MB acquisition

Scanfil's share price has risen by over 20% since the MB acquisition published last Sunday. We believe the share price rally was driven by the increased weight of the defense sector, which has strong prospects and has grown due to acquisitions, and positive comments on the outlook from Nordic peers. Although the outlook for the defense sector is strong and its opening to Scanfil is positive, we do not yet see a need to drastically change the stock's valuation multiples. The defense sector will be Scanfil's smallest customer segment in the near term with a revenue share of just under 10%. Based on our estimates for 2025 and 2026, Scanfil's adjusted P/E ratios are 16x and 13x, and the corresponding EV/EBITA ratios are 14x and 11x. In our opinion, the multiples for next year, which depend on the market situation picking up, are also neutral, considering the acquisitions, so in the short term, we believe the valuation of the stock has tightened. Correspondingly, the expected annual return, consisting of earnings growth, the downside in the multiples, and a 2-3% dividend yield, remains modest. Also, when viewed against the DCF value, the upside in the share has been exhausted.

#### Recommendation

#### Reduce

(was Reduce)

## **Target price:**

**EUR 10.50** (was EUR 9.00)

## **Share price:**

EUR 11.32

#### **Business risk**



#### Valuation risk



	2024	<b>2025</b> e	<b>2026</b> e	<b>2027</b> e
Revenue	780	844	1006	1076
growth-%	-13%	8%	19%	7%
EBIT adj.	54.9	60.9	75.7	83.0
EBIT-% adj.	7.0 %	7.2 %	7.5 %	7.7 %
Net Income	38.9	42.4	51.3	57.2
EPS (adj.)	0.62	0.70	0.85	0.94
P/E (adj.)	13.3	16.3	13.4	12.1
P/B	1.9	2.3	2.1	1.9
Dividend yield-%	2.9 %	2.3 %	2.5 %	2.7 %
EV/EBIT (adj.)	10.2	13.8	11.0	9.8
EV/EBITDA	7.6	10.4	8.2	7.4
EV/S	0.7	1.0	0.8	8.0


Source: Inderes

#### Guidance


(Unchanged)

Scanfil estimates that in 2025, its revenue is 780-920 MEUR and adjusted EBITA 55-68 MEUR

## **Share price**



## **Revenue and EBIT-% (adj.)**



## **EPS** and dividend



#### Source: Inderes

## **Value drivers**

- Organic growth with the market and key customers
- Benefiting from the green trend
- Accelerating growth through M&A
- Strong financial track record
- Increase in acceptable valuation

## **Risk factors**

- Demand comes partly from somewhat cyclical sectors
- Demand is investment-driven and therefore somewhat sensitive to interest rates
- Tightening competition and changes in the competitive field
- Limited pricing power
- Inflation

Valuation	2025e	2026e	2027e
Share price	11.3	11.3	11.3
Number of shares, millions	65.3	65.3	65.3
Market cap	740	740	740
EV	838	831	813
P/E (adj.)	16.3	13.4	12.1
P/E	17.5	14.4	12.9
P/B	2.3	2.1	1.9
P/S	0.9	0.7	0.7
EV/Sales	1.0	0.8	0.8
EV/EBITDA	10.4	8.2	7.4
EV/EBIT (adj.)	13.8	11.0	9.8
Payout ratio (%)	40.1 %	35.7 %	34.3 %
Dividend yield-%	2.3 %	2.5 %	2.7 %

## **Earnings growth still lacked momentum in Q2**

## Revenue grew moderately supported by the SRX acquisition in Q2

In Q2, Scanfil's revenue increased by 3% to 202 MEUR from a modest comparison level. Organically, we suspect revenue declined further by some 1%, as the SRX acquisition supported revenue by some 4%, or 8.8 MEUR. In Q2, revenue development was more subdued than we expected, especially in terms of organic growth. The Americas, which continued its strong growth of over 30%, exceeded expectations, but especially in Central European factories dependent on cleantech projects, revenue was lower than our forecast. For APAC and Northern Europe, deviations from our forecasts were smaller.

## The operating result remained at the comparison period level in Q2

Scanfil's adjusted EBITA shrunk by 4% to 14.2 MEUR in Q2, which fell short of our overly optimistic forecast as revenue remained below our expectations. Profitability (adj. EBITA-

%) settled at 7.0%, similar to Scanfil's baseline in recent years. In terms of profitability, the Americas' result and profitability fell short of our forecasts despite strong growth due to a weaker product mix, while APAC achieved a stronger-than-expected and quite good margin. In Central and Northern Europe, profitability met our expectations, but earnings fell short of our estimates due to revenue-related reasons.

In the lower lines, Scanfil reported unsurprisingly small 0.3 MEUR one-off costs (not in forecasts) related to the ADCO acquisition in Q2, while financial expenses likely turned positive due to currency-based reasons, and the tax rate fell slightly below our estimate. Thus, the Q2 EPS of EUR 0.16 was one cent below the comparison figure and our estimate. In terms of cash flow, Scanfil's Q2 was decent, although cash flow from operating activities decreased by nearly 40% to 23 MEUR year-on-year, supported by an exceptionally strong release of working capital.

### Balance sheet remains solid even after the acquisitions

Scanfil's net debt to EBITDA ratio was 0.4x (cf. target below 1.5x). The combined debt-free price of the ADCO and MB acquisitions, reasonably financed with debt, is 95 MEUR, excluding the earn-out for the MB acquisition. This will change the company's balance sheet structure significantly during H2, but we estimate that the net debt/pro forma EBITDA ratio will remain in the range of 1x-1.5x also in H2 when the acquisitions are completed. The company also has or will have contingent considerations from the SRX and MB acquisitions totaling approximately 60 MEUR, but this will not affect net debt until the earn-out is fully or partially realized. Most of the earn-outs may also materialize only in 2026-2027, once the scale of the MB transaction's earn-out has been determined. However, we do not expect the company to make acquisitions in the short term, but the need to integrate ADCO and MB into Scanfil before further moves is a greater reason for our view than balance sheet constraints.

Estimates	Q2'24	Q2'25	Q2'25e	Q2'25e	Consensus	Difference (%)	2025e
MEUR / EUR	Comparison	Actualized	Inderes	Consensus	Low High	Act. vs. inderes	Inderes
Revenue	196	202	213			-5%	844
EBITA (adj.)	14.3	14.2	15.4			-8%	60.9
EBIT	13.9	13.3	14.8			-10%	56.8
PTP	14.0	13.5	14.4			-6%	54.6
EPS (reported)	0.17	0.16	0.17			-7%	0.65
D	40.0.0/	0.00	0.00			<b>5</b> 0	0.00/
Revenue growth-%	-19.6 %	3.3 %	9.0 %			-5.6 pp	8.2 %
EBITA-% (adj.)	7.3 %	7.0 %	7.2 %			-0.2 pp	7.2 %

## We included the ADCO and MB deals, to be completed in H2, in our estimates

#### The reiterated guidance was in line with our expectations

Scanfil reiterated its guidance for 2025 in its Q2 report of 780-920 MEUR revenue and 55-68 MEUR adjusted EBIT. The reiterated guidance was in line with our expectations. Despite the macro uncertainties, the company commented positively on H2's outlook. In July, Kitron and Note did the same in their reports. The optimism was at least partly driven by he improved outlook of project-driven customers, to which the company should have reasonable visibility. In addition, only a small portion of the annualized 187 MEUR revenue from projects won last year has materialized in H1 due to normal start-up and ramp-up delays, and these deals will be more clearly reflected in the company's revenue in H2. Scanfil did not comment that the trade war had significantly affected the forecasts received from its customers, despite the prevailing uncertainties. However, we note that the risks in this respect are not yet over, but the entry into force of new significant tariffs could alter the outlook even abruptly. Without an escalation of tariff risks, we believe that the economic outlook and Scanfil's

investment-driven demand have the potential to develop positively in the coming years.

The guidance does not contain the ADCO and MB acquisitions announced in the summer. Given the H1 development trending more towards the lower end of the guidance range, the positive outlook despite H2 uncertainties, and the acquisitions only materializing in H2, we expect the company to maintain its guidance unchanged in H2 as well.

#### Promising acquisitions significantly raised our forecasts


We have added the ADCO and MB acquisitions to Scanfil's forecasts starting from Q3 and Q4, but organically, after a fairly neutral Q2 report (incl. the Q2 forecast miss and positive comments on recent demand trends), we made no material changes to the company's growth and profitability forecasts. We expect Scanfil's revenue to turn to organic growth from H2 onwards, driven by project wins and a gradual recovery in the market situation.

The promising profiles of the ADCO and MB acquisitions and putting the strong balance sheet to work increased our revenue and adjusted EBITA estimates for Scanfil in the coming years by approximately 15%. We have cut our adjusted EPS estimates by over 10%, as debt-financed acquisitions increased financial expenses, and the company also retains a small minority stake from the ADCO transaction. PPA amortizations are also likely to increase due to the acquisitions, but we still treat them as adjustments like non-recurring items. We expect about half of the earn-outs of MB and SRX to materialize in 2026-2027. This is a rough estimate that will be specified later.

We expect the adjusted EPS to grow at a rate of some 15% by 2028, driven by acquisitions and a gradually recovering economic situation. The main forecast risks are related to external demand factors such as the global economy. Internally, we believe the company is in fairly good shape, although we suspect the integration of two nearly simultaneous acquisitions will slightly increase the risk level associated with the company's operations in the near term.

Estimate revisions MEUR / EUR	2025e Old	2025e New	Change %	2026e Old	2026e New	Change %	2027e Old	2027e New	Change %
Revenue	831	844	2%	876	1006	15%	937	1076	15%
EBIT (exc. NRIs)	59.8	60.9	2%	63.8	75.7	19%	69.9	83.0	19%
EBIT	57.3	56.8	-1%	61.0	70.6	16%	67.1	77.9	16%
PTP	55.1	54.6	-1%	59.9	66.1	10%	66.5	73.7	11%
EPS (excl. NRIs)	0.69	0.70	1%	0.75	0.85	13%	0.83	0.94	13%
DPS	0.25	0.26	4%	0.27	0.28	4%	0.29	0.30	3%

## Risk profile of the business model



## **Fully priced on a 12 month perspective**

#### Next year's multiples are already neutral

Scanfil's share price has risen by more than 20% since the MB acquisition published last Sunday. We believe the share price rally has been driven by the increased weight of the defense sector with favorable prospects as a result of acquisitions, as well as Note's and Kitron's positive comments on the H2 outlook. Although the outlook for the defense sector is good and its opening to Scanfil is positive, we do not yet see a need to drastically change the stock's valuation multiples, as the defense sector is likely to be Scanfil's smallest customer segment in the near future, with a revenue share of just under 10%. We believe that Scanfil's adjusted P/E multiple of 12x-15x and adjusted EV/EBITA multiple of 10x-12x are still acceptable based on Scanfil's growth and return on capital potential, the stock's risk level, and its largely strong historical track record.

In our estimate, Scanfil's P/E ratios for 2025 and 2026 are around 16x and 13x, while the corresponding EV/EBITA ratios are some 14x and 11x. We expect dividend yields to settle at a level of 2-3% in the coming years. The earningsbased valuation is above Scanfil's historical medians with 2025 multiples. For next year, the multiples are on par with medium-term median levels. Therefore, in our view, the stock's valuation has become more demanding following the recent share price surge, especially considering that the realization of our 2026 forecasts, which fully account for the acquisitions, also requires a sustainable improvement in the operating environment. Thus, we consider the stock to be fully priced in the short term. We find the expected return, consisting of earnings growth, a dividend yield of around 3% and the downside in the multiples (Q2'25 LTM ACT P/E 19x) modest.

## Peer group valuation and especially DCF reflect full valuation


Compared to a peer group of global contract manufacturers, Scanfil's earnings-based valuation is rather neutral. We believe Scanfil deserves a small premium due to its long-term track record and positioning in industrial electronics with better margin potential, but we feel the peer group is already quite expensive in the short term (2025e: P/E 17x, EV/EBIT 15x). Therefore, we do not find the relative valuation of the share too attractive. Among the Nordic peers, Kitron and Note are valued clearly higher than Scanfil. In our opinion, the valuation of core peers already entails more risks than potential, which is why we do not base our view on the assumption that Scanfil's stock would be priced more strongly through peers.


Our DCF model for Scanfil is also above the price at around EUR 10.5 per share. Thus, also in light of the DCF, the stock is fully valued, even though we also slightly raised our long-term forecasts due to the acquisitions. The model's average profitability corresponds to Scanfil's realized margin level (and is slightly below the target level of 7-8%). We also slightly lowered our model's required return (CoE) to 9.2% due to the opening of the defense sector and the containment of trade war risks (cf. we raised our cost of equity in April when the trade war flared up). Considering these factors and Scanfil's reasonable long-term predictability, we also give a reasonable weight to the DCF signals in Scanfil despite the chronic inaccuracy of the method.


Valuation	<b>2025</b> e	<b>2026e</b>	<b>2027</b> e
Share price	11.3	11.3	11.3
Number of shares, millions	65.3	65.3	65.3
Market cap	740	740	740
EV	838	831	813
P/E (adj.)	16.3	13.4	12.1
P/E	17.5	14.4	12.9
P/B	2.3	2.1	1.9
P/S	0.9	0.7	0.7
EV/Sales	1.0	0.8	0.8
EV/EBITDA	10.4	8.2	7.4
EV/EBIT (adj.)	13.8	11.0	9.8
Payout ratio (%)	40.1 %	35.7 %	34.3 %
Dividend yield-%	2.3 %	2.5 %	2.7 %

## **Valuation table**

Valuation	2020	2021	2022	2023	2024	<b>2025</b> e	<b>2026</b> e	<b>2027</b> e	<b>2028</b> e
Share price	6.52	7.46	6.58	7.83	8.25	11.3	11.3	11.3	11.3
Number of shares, millions	64.5	64.5	64.5	65.3	65.3	65.3	65.3	65.3	65.3
Market cap	420	481	424	511	538	740	740	740	740
EV	439	541	510	563	560	838	831	813	774
P/E (adj.)	13.0	15.8	12.1	10.4	13.3	16.3	13.4	12.1	11.5
P/E	11.4	16.2	12.1	10.6	13.8	17.5	14.4	12.9	12.2
P/B	2.3	2.3	1.9	1.9	1.9	2.3	2.1	1.9	1.7
P/S	0.7	0.7	1.9	0.6	0.7	0.9	0.7	0.7	0.7
EV/Sales	0.7	0.8	0.5	0.6	0.7	1.0	0.8	0.8	0.7
EV/EBITDA	7.2	9.8	8.1	7.0	7.6	10.4	8.2	7.4	6.8
EV/EBIT (adj.)	11.2	13.4	11.2	9.0	10.2	13.8	11.0	9.8	8.9
Payout ratio (%)	29.7 %	41.1 %	38.7 %	31.1 %	40.2 %	40.1 %	35.7 %	34.3 %	34.5 %
Dividend yield-%	2.6 %	2.5 %	3.2 %	2.9 %	2.9 %	2.3 %	2.5 %	2.7 %	2.8 %







## **Peer group valuation**

Peer group valuation	Market cap	EV	EV/	EBIT	EV/E	BITDA	EV	//S	P	/E	Dividend	l yield-%	P/B
Company	MEUR	MEUR	2025e	2026e	2025e	2026e	2025e	<b>2026e</b>	2025e	2026e	2025e	2026e	2025e
Incap	353	322	10.9	9.6	9.1	8.2	1.4	1.2	16.0	13.9			2.3
Kitron	1108	1203	19.7	16.0	15.2	12.7	1.7	1.5	27.0	20.8	1.3	1.9	4.7
Hanza	383	525	14.5	12.0	8.7	7.5	1.0	0.9	17.7	13.4	1.2	1.9	2.3
Pegatron	6324	5755	12.3	10.3	6.1	5.4	0.2	0.2	12.5	11.8	5.5	5.6	1.0
Celestica	15813	16389	24.7	20.8	21.0	17.9	1.7	1.5	31.7	26.6			9.4
Flextronics	16709	17973	14.6	13.2	10.8	9.8	0.8	0.8	19.9	17.6			4.1
Foxconn	66262	65070	9.7	8.2	6.7	5.9	0.3	0.2	12.2	10.8	4.1	4.7	1.3
Jabil	20202	21448	16.0	14.4	10.8	9.9	0.9	0.8	23.4	20.2	0.2	0.2	15.1
Hana Microelectronics	495	233	6.2	5.2	2.9	2.6	0.4	0.4	14.4	12.3	3.9	4.9	0.7
TT Electronics	217	328	9.9	7.7	6.0	5.2	0.6	0.6	10.6	7.8	3.3	4.1	0.9
Fabrinet	9191	8360	27.6	24.1	23.7	20.6	2.9	2.5	29.3	25.6			5.4
Universal Scientific	3779	3151	14.2	10.8	8.5	6.9	0.4	0.4	18.2	14.1	2.1	2.5	1.4
Venture Corporation	2395	1535	9.2	8.8	8.0	7.7	0.9	0.8	15.4	14.8	6.1	6.1	1.2
Plexus	3203	3116	15.4	13.7	11.4	10.4	0.9	0.8	19.6	18.0			2.7
Note	488	497	14.5	13.0	10.9	9.8	1.4	1.3	19.1	16.7	2.5	1.0	3.2
Katek	309	394	7.5	7.7	5.1	5.2	0.4	0.4	9.4	9.8			1.6
Lacroix	39	146	19.7	5.8	5.9	3.7	0.3	0.3	4.8	3.0		6.6	
Scanfil (Inderes)	740	838	13.8	11.0	10.4	8.2	1.0	0.8	16.3	13.4	2.3	2.5	2.3
Average			14.5	11.8	10.0	8.8	0.9	0.9	17.7	15.1	3.0	3.6	3.6
Median			14.5	10.8	8.7	7.7	0.9	0.8	17.7	14.1	2.9	4.1	2.3
Diff-% to median			-5%	2%	19%	6%	17%	<b>2</b> %	-8%	-5%	-21%	-40%	1%

Source: Refinitiv / Inderes

## **Income statement**

Income statement	2023	Q1'24	Q2'24	Q3'24	Q4'24	2024	Q1'25	Q2'25	Q3'25e	Q4'25e	2025e	<b>2026</b> e	2027e	2028e
Revenue	902	199	196	173	212	780	193	202	200	249	844	1006	1076	1127
Americas	37.5	8.6	8.8	9.7	10.9	38.0	11.7	11.8	13.1	18.9	55.5	76.5	79.6	83.6
APAC	184	40.1	45.5	42.7	61.0	189	52.2	59.5	61.9	63.5	237	254	272	285
Central Europe	390	84.6	76.1	65.4	77.2	303	69.5	67.5	68.7	100.0	306	419	452	475
Northern Europe	309	69.1	67.2	56.5	64.6	257	60.6	65.6	58.2	67.9	252	262	278	289
Eliminations / NRIs	-19.3	-3.5	-2.1	-1.0	-1.5	-8.1	-1.4	-2.2	-1.5	-1.5	-6.6	-6.0	-6.0	-6.0
EBITDA	80.4	17.7	19.0	17.5	19.8	74.0	17.6	19.1	19.6	24.3	80.7	102	109	113
Depreciation	-19.1	-5.0	-5.1	-5.1	-5.9	-21.1	-5.7	-5.9	-5.9	-6.4	-23.9	-31.0	-31.4	-31.4
EBIT (excl. NRI)	62.8	13.1	14.3	12.8	14.7	54.9	12.6	14.2	14.9	19.1	60.9	75.7	83.0	86.9
EBIT	61.3	12.7	13.9	12.4	13.9	52.9	11.9	13.3	13.7	17.9	56.8	70.6	77.9	81.8
Americas	2.7	0.5	0.8	0.8	1.1	3.2	0.8	0.6	1.0	2.0	4.4	6.0	6.7	7.2
APAC	10.7	3.0	4.4	3.9	3.9	15.2	3.6	5.1	5.3	5.4	19.3	20.3	21.7	22.7
Central Europe	31.6	6.9	5.1	4.4	6.2	22.6	5.2	4.9	5.1	7.6	22.8	33.8	37.6	39.3
Northern Europe	18.1	2.8	4.0	3.7	3.9	14.4	3.1	3.7	3.6	4.1	14.5	15.6	17.1	17.6
Eliminations / NRIs	-1.5	-0.4	-0.4	-0.4	-0.7	-1.9	-0.7	-1.0	-1.2	-1.2	-4.1	-5.1	-5.1	-5.1
Net financial items	0.3	0.2	0.0	-0.2	-1.5	-1.5	-1.2	0.2	-0.4	-0.8	-2.2	-4.4	-4.2	-3.7
PTP	61.7	12.9	14.0	12.2	12.4	51.4	10.7	13.5	13.3	17.1	54.6	66.1	73.7	78.1
Taxes	-13.4	-3.1	-3.2	-3.1	-3.1	-12.5	-2.4	-3.0	-2.9	-3.8	-12.1	-14.5	-16.2	-17.2
Minority interest	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-0.1	-0.1	-0.2	-0.3	-0.3	-0.4
Net earnings	48.3	9.8	10.8	9.1	9.3	38.9	8.3	10.5	10.4	13.3	42.4	51.3	57.2	60.6
Net earnings	48.2	9.8	10.8	9.1	9.3	38.9	8.3	10.5	10.4	13.3	42.4	51.3	57.2	60.6
EPS (adj.)	0.76	0.15	0.17	0.14	0.15	0.62	0.14	0.17	0.17	0.22	0.70	0.85	0.94	0.99
EPS (rep.)	0.74	0.15	0.17	0.14	0.14	0.60	0.13	0.16	0.16	0.20	0.65	0.78	0.88	0.93
Key figures	2023	Q1'24	Q2'24	Q3'24	Q4'24	2024	Q1'25	Q2'25	Q3'25e	Q4'25e	2025e	<b>2026</b> e	2027e	2028e
Revenue growth-%	6.9 %	-11.4 %	-19.6 %	-18.6 %	-3.9 %	-13.5 %	-3.2 %	3.4 %	15.6 %	17.3 %	8.2 %	19.2 %	6.9 %	4.8 %
Adjusted EBIT growth-%	38.3 %	-15.5 %	-20.1 %	-17.9 %	6.4 %	-12.6 %	-3.8 %	-0.7 %	16.7 %	30.3 %	10.9 %	24.3 %	9.7 %	4.7 %
EBITDA-%	8.9 %	8.9 %	9.7 %	10.1 %	9.3 %	9.5 %	9.2 %	9.5 %	9.8 %	9.8 %	9.6 %	10.1 %	10.2 %	10.0 %
Adjusted EBIT-%	7.0 %	6.6 %	7.3 %	7.4 %	6.9 %	7.0 %	6.5 %	7.0 %	7.5 %	7.7 %	7.2 %	7.5 %	7.7 %	7.7 %
Net earnings-%	5.3 %	4.9 %	5.5 %	5.2 %	4.4 %	5.0 %	4.3 %	5.2 %	5.2 %	5.3 %	5.0 %	5.1 %	5.3 %	5.4 %

Source: Inderes

Full-year EPS are calculated using the year-end number of shares.

## **Balance sheet**

Assets	2023	2024	2025e	2026e	2027e
Non-current assets	112	152	251	253	223
Goodwill	7.7	29.1	99.1	99.1	69.1
Intangible assets	10.4	20.0	20.1	20.2	20.3
Tangible assets	85.3	94.9	123	125	125
Associated companies	0.0	0.0	0.0	0.0	0.0
Other investments	0.5	0.5	0.5	0.5	0.5
Other non-current assets	0.0	0.0	0.0	0.0	0.0
Deferred tax assets	7.7	7.7	7.7	7.7	7.7
Current assets	406	387	414	457	487
Inventories	209	168	190	211	224
Other current assets	2.7	4.9	4.9	4.9	4.9
Receivables	174	165	186	201	215
Cash and equivalents	21.2	48.5	33.8	40.2	43.0
Balance sheet total	518	539	697	737	731


Liabilities & equity	2023	2024	<b>2025</b> e	2026e	2027e
Equity	266	291	321	356	395
Share capital	2.0	2.0	2.0	2.0	2.0
Retained earnings	230	256	282	317	355
Hybrid bonds	0.0	0.0	0.0	0.0	0.0
Revaluation reserve	0.0	0.0	0.0	0.0	0.0
Other equity	33.8	33.4	34.1	34.1	34.1
Minorities	0.0	0.0	3.0	3.0	3.0
Non-current liabilities	25.4	63.7	157	142	88.8
Deferred tax liabilities	5.7	9.7	9.7	9.7	9.7
Provisions	1.1	1.8	1.8	1.8	1.8
Interest bearing debt	18.6	41.9	86.5	86.6	77.3
Convertibles	0.0	0.0	0.0	0.0	0.0
Other long term liabilities	0.0	10.3	59.0	44.0	0.0
Current liabilities	227	184	218	239	248
Interest bearing debt	54.3	27.8	38.2	38.2	32.8
Payables	167	154	177	198	212
Other current liabilities	5.5	2.8	2.8	2.8	2.8
Balance sheet total	518	539	697	737	731

## **DCF-calculation**


DCF model	2024	<b>2025</b> e	<b>2026</b> e	<b>2027</b> e	<b>2028</b> e	<b>2029</b> e	<b>2030</b> e	<b>2031</b> e	<b>2032</b> e	<b>2033</b> e	<b>2034</b> e	TERM
Revenue growth-%	-13.5 %	8.2 %	19.2 %	6.9 %	4.8 %	4.0 %	4.0 %	3.5 %	3.5 %	3.0 %	2.0 %	2.0 %
EBIT-%	6.8 %	6.7 %	7.0 %	7.2 %	7.3 %	7.1 %	6.9 %	6.7 %	6.7 %	6.6 %	6.6 %	6.6 %
EBIT (operating profit)	52.9	56.8	70.6	77.9	81.8	83.2	84.1	84.5	86.8	89.3	91.1	
+ Depreciation	21.1	23.9	31.0	31.4	31.4	31.6	30.8	30.2	30.2	27.7	26.8	
- Paid taxes	-8.5	-12.1	-14.5	-16.2	-17.2	-17.9	-18.3	-18.5	-19.0	-19.6	-20.1	
- Tax, financial expenses	-0.5	-0.6	-1.1	-1.0	-0.9	-0.5	-0.4	-0.3	-0.3	-0.3	-0.3	
+ Tax, financial income	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.3	0.3	0.4	
- Change in working capital	31.1	-18.6	-15.9	-12.7	-8.6	-7.1	-7.3	-6.2	-9.0	-8.0	-5.5	
Operating cash flow	96.3	49.5	70.2	79.5	86.6	89.4	89.2	89.9	89.0	89.4	92.4	
+ Change in other long-term liabilities	11.0	48.7	-15.0	-44.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
- Gross CAPEX	-61.7	-154.1	-28.1	3.9	-26.1	-26.1	-26.1	-27.1	-27.1	-27.1	-27.2	
Free operating cash flow	45.6	-55.9	27.1	39.4	60.5	63.3	63.1	62.8	61.9	62.3	65.2	
+/- Other	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
FCFF	45.6	-55.9	27.1	39.4	60.5	63.3	63.1	62.8	61.9	62.3	65.2	1010
Discounted FCFF		-53.8	24.0	32.2	45.5	43.9	40.2	36.9	33.5	31.0	29.9	464
Sum of FCFF present value		727	781	757	725	679	635	595	558	525	494	464
Enterprise value DCF		727										
- Interest bearing debt		-69.7				Cas	h flow distri	bution				
+ Cash and cash equivalents		48.5				Cas	ii iiow distii	bution				
-Minorities		-7.0										
-Dividend/capital return		-15.7										
Equity value DCF		683	2025e-2029e	е	1	3%						
Equity value DCF per share		10.5										
WACC												
Tax-% (WACC)		23.0 %	2030e-2034e	е			24%					
Target debt ratio (D/(D+E)		10.0 %										
Cost of debt		4.5 %										
Equity Beta		1.40										
Market risk premium		4.75%	TERM	1							64%	
Liquidity premium		0.00%										
Risk free interest rate		2.5 %										
Cost of equity		9.2 %				- 2025 - 222		2024 75	-DM			
Weighted average cost of capital (WACC)		8.6 %				■ 2025e-202	29e ■2030e	-2034e ■TE	KIVI			

## DCF sensitivity calculations and key assumptions in graphs







#### Sensitivity of DCF to changes in the terminal EBIT margin



#### Sensitivity of DCF to changes in the risk-free rate



#### Growth and profitability assumptions in the DCF calculation



## **Summary**

Income statement	2022	2023	2024	<b>2025e</b>	2026e	Per share data	2022
Revenue	844	902	780	844	1006	EPS (reported)	0.54
EBITDA	62.9	80.4	74.0	80.7	101.6	EPS (adj.)	0.54
EBIT	45.4	61.3	52.9	56.8	70.6	OCF / share	0.24
PTP	41.7	61.7	51.4	54.6	66.1	FCF / share	-0.10
Net Income	35.0	48.2	38.9	42.4	51.3	Book value / share	3.51
Extraordinary items	0.0	-1.5	-1.9	-4.1	-5.1	Dividend / share	0.21
Balance sheet	2022	2023	2024	<b>2025</b> e	2026e	Growth and profitability	2022
Balance sheet total	526	518	539	697	737	Revenue growth-%	21%
Equity capital	227	266	291	321	356	EBITDA growth-%	14%
Goodwill	7.7	7.7	29.1	99.1	99.1	EBIT (adj.) growth-%	13%
Net debt	85.5	51.7	21.2	90.9	84.6	EPS (adj.) growth-%	15%
						EBITDA-%	7.5 %
Cash flow	2022	2023	2024	<b>2025</b> e	2026e	EBIT (adj.)-%	5.4 %
EBITDA	62.9	80.4	74.0	80.7	101.6	EBIT-%	5.4 %
Change in working capital	-39.9	-2.0	31.1	-18.6	-15.9	ROE-%	16.1 %
Operating cash flow	15.7	66.3	96.3	49.5	70.2	ROI-%	14.5 %
CAPEX	-22.6	-24.3	-61.7	-154.1	-28.1	Equity ratio	43.1 %
Free cash flow	-6.7	42.3	45.6	-55.9	27.1	Gearing	37.7 %
Valuation multiples	2022	2023	2024	2025e	<b>2026</b> e		
EV/S	0.6	0.6	0.7	1.0	0.8		
EV/EBITDA	8.1	7.0	7.6	10.4	8.2		
EV/EBIT (adj.)	11.2	9.0	10.2	13.8	11.0		
P/E (adj.)	12.1	10.4	13.3	16.3	13.4		
P/B	1.9	1.9	1.9	2.3	2.1		

0.76 0.62 0.70 0.85 1.02 1.48 0.76 1.07 0.65 0.70 -0.85 0.41 4.08 4.46 4.87 5.40 0.23 0.24 0.26 0.28 2023 2024 **2025**e **202**6e 7% 19% -13% 8% 28% -8% 9% 26% 38% -13% 11% 24% 39% -18% 12% 21% 8.9 % 9.5 % 9.6 % 10.1 % 7.0 % 7.0 % 7.2 % 7.5 % 6.8 % 6.8 % 6.7% 7.0 % 19.6 % 14.0 % 13.9 % 15.3 % 18.3 % 15.3 % 14.2 % 15.4 % 51.3 % 54.0 % 46.1% 48.3 % 19.4 % 7.3 % 28.3 % 23.8 %

2023

0.74

2024

0.60

Source: Inderes

Dividend-%

3.2 %

2.9 %

2.9 %

2.3 %

2.5 %

**2026**e

0.78

2025e

0.65

## Disclaimer and recommendation history

Reduce

The information presented in Inderes reports is obtained from several different public sources that Inderes considers to be reliable. Inderes aims to use reliable and comprehensive information, but Inderes does not guarantee the accuracy of the presented information. Any opinions, estimates and forecasts represent the views of the authors. Inderes is not responsible for the content or accuracy of the presented information. Inderes and its employees are also not responsible for the financial outcomes of investment decisions made based on the reports or any direct or indirect damage caused by the use of the information. The information used in producing the reports may change quickly. Inderes makes no commitment to announcing any potential changes to the presented information and opinions.

The reports produced by Inderes are intended for informational use only. The reports should not be construed as offers or advice to buy, sell or subscribe investment products. Customers should also understand that past performance is not a guarantee of future results. When making investment decisions, customers must base their decisions on their own research and their estimates of the factors that influence the value of the investment and take into account their objectives and financial position and use advisors as necessary. Customers are responsible for their investment decisions and their financial outcomes.

Reports produced by Inderes may not be edited, copied or made available to others in their entirety, or in part, without Inderes' written consent. No part of this report, or the report as a whole, shall be transferred or shared in any form to the United States, Canada or Japan or the citizens of the aforementioned countries. The legislation of other countries may also lay down restrictions pertaining to the distribution of the information contained in this report. Any individuals who may be subject to such restrictions must take said restrictions into account.

Inderes issues target prices for the shares it follows. The recommendation methodology used by Inderes is based on the share's 12-month expected total shareholder return (including the share price and dividends) and takes into account Inderes' view of the risk associated with the expected returns. The recommendation policy consists of four tiers: Sell, Reduce, Accumulate and Buy. As a rule, Inderes' investment recommendations and target prices are reviewed at least 2–4 times per year in connection with the companies' interim reports, but the recommendations and target prices may also be changed at other times depending on the market conditions. The issued recommendations and target prices do not guarantee that the share price will develop in line with the estimate. Inderes primarily uses the following valuation methods in determining target prices and recommendations: Cash flow analysis (DCF), valuation multiples, peer group analysis and sum of parts analysis. The valuation methods and target price criteria used are always company-specific and they may vary significantly depending on the company and (or) industry.

Inderes' recommendation policy is based on the following distribution relative to the 12-month risk-adjusted expected total shareholder return.

Buy	The 12-month risk-adjusted expected shareholder return of
	the share is very attractive

Accumulate The 12-month risk-adjusted expected shareholder return of the share is attractive

The 12-month risk-adjusted expected shareholder return of

the share is weak

Sell The 12-month risk-adjusted expected shareholder return of

the share is very weak

The assessment of the 12-month risk-adjusted expected total shareholder return based on the above-mentioned definitions is company-specific and subjective. Consequently, similar 12-month expected total shareholder returns between different shares may result in different recommendations, and the recommendations and 12-month expected total shareholder returns between different shares should not be compared with each other. The counterpart of the expected total shareholder return is Inderes' view of the risk taken by the investor, which varies considerably between companies and scenarios. Thus, a high expected total shareholder return does not necessarily lead to positive performance when the risks are exceptionally high and, correspondingly, a low expected total shareholder return does not necessarily lead to a negative recommendation if Inderes considers the risks to be moderate.

The analysts who produce Inderes' research and Inderes employees cannot have 1) shareholdings that exceed the threshold of significant financial gain or 2) shareholdings exceeding 1% in any company subject to Inderes' research activities. Inderes Oyj can only own shares in the target companies it follows to the extent shown in the company's model portfolio investing real funds. All of Inderes Oyj's shareholdings are presented in itemised form in the model portfolio. Inderes Oyj does not have other shareholdings in the target companies analysed. The remuneration of the analysts who produce the analysis are not directly or indirectly linked to the issued recommendation or views. Inderes Oyj does not have investment bank operations.


Inderes or its partners whose customer relationships may have a financial impact on Inderes may, in their business operations, seek assignments with various issuers with respect to services provided by Inderes or its partners. Thus, Inderes may be in a direct or indirect contractual relationship with an issuer that is the subject of research activities. Inderes and its partners may provide investor relations services to issuers. The aim of such services is to improve communication between the company and the capital markets. These services include the organisation of investor events, advisory services related to investor relations and the production of investor research reports.

More information about research disclaimers can be found at www.inderes.fi/research-disclaimer.

Inderes has made an agreement with the issuer and target of this report, which entails compiling a research report.

#### Recommendation history (>12 mo)

Date	Recommendation	Target	Share price
4/26/2019	Accumulate	4.50 €	4.20 €
8/12/2019	Accumulate	4.50 €	4.04 €
10/28/2019	Accumulate	4.75 €	4.35 €
1/17/2020	Accumulate	5.25 €	4.94 €
2/20/2020	Accumulate	5.60 €	5.20 €
3/23/2020	Accumulate	4.25 €	3.73 €
4/25/2020	Accumulate	5.00 €	4.48 €
8/5/2020	Accumulate	5.50 €	5.18 €
8/10/2020	Accumulate	6.00 €	5.56 €
10/28/2020	Buy	6.00 €	5.14 €
12/15/2020	Accumulate	6.30 €	5.96 €
3/19/2021	Accumulate	7.30 €	6.90 €
4/9/2021	Accumulate	8.00€	7.56 €
4/26/2021	Accumulate	8.60 €	8.08€
6/14/2021	Accumulate	8.60 €	8.06€
8/8/2021	Accumulate	8.75 €	8.30 €
10/14/2021	Accumulate	8.75 €	7.94 €
10/27/2021	Accumulate	8.75 €	7.78 €
12/13/2021	Reduce	8.30 €	7.96 €
2/16/2022	Accumulate	8.00€	7.08 €
2/23/2022	Accumulate	8.00€	6.84 €
4/19/2022	Accumulate	8.00€	7.04 €
6/1/2022	Accumulate	7.60 €	6.66 €
7/14/2022	Accumulate	7.60 €	6.98 €
8/8/2022	Accumulate	7.60 €	6.76 €
10/27/2022	Buy	7.25 €	5.84 €
2/22/2023	Accumulate	8.25 €	7.74 €
4/23/2023	Reduce	9.00 €	9.13 €
4/26/2023	Reduce	9.00 €	9.67 €
7/6/2023	Reduce	9.50 €	10.38 €
7/31/2023	Reduce	10.00 €	10.56 €
8/7/2023	Reduce	10.00 €	10.64 €
9/14/2023	Accumulate	10.00 €	8.51 €
10/16/2023	Accumulate	9.00 €	7.64 €
10/30/2023	Accumulate	9.00 €	7.38 €
2/25/2024	Accumulate	9.00 €	7.71 €
4/25/2024	Accumulate	9.00 €	7.78 €
6/11/2024	Accumulate	9.00 €	7.48 €
8/7/2024	Accumulate	9.00 €	7.35 €
10/7/2024	Accumulate	9.00 €	7.38 €
10/28/2024	Accumulate	8.70 €	7.87 €
2/24/2025	Accumulate	9.40 €	8.76 €
4/9/2025	Accumulate	9.00 €	8.08€
4/25/2025	Reduce	9.00 €	8.76 €
7/17/2025	Reduce	10.50 €	11.32 €



# CONNECTING INVESTORS AND COMPANIES.

Inderes connects investors and listed companies.

We serve over 400 Nordic listed companies that want to better serve investors. The Inderes community is home to over 70,000 active investors.

We provide listed companies with solutions that enable seamless and effective investor relations. The Inderes service is built on four cornerstones for high-quality investor relations: Equity Research, Events, IR Software, and Annual General Meetings (AGM).

Inderes operates in Finland, Sweden, Norway, and Denmark and is listed on the Nasdaq First North Growth Market.

Inderes was created by investors, for investors.

Inderes Ab

Vattugatan 17, 5tr Stockholm

+46 8 411 43 80

inderes.se

**Inderes Oyj** 

Porkkalankatu 5 00180 Helsinki

+358 10 219 4690

inderes.fi

